RHB-104 is a proprietary and potentially groundbreaking antibiotic combination therapy in oral capsule formulation, with potent intracellular, anti-mycobacterial and anti-inflammatory properties. The MAP US study is the first
FCS is a rare genetic disease characterized by extremely high triglyceride levels and risk of pancreatitis. In a Phase 2 study published in the NEJM in December 2014,
Horizon’s proposal represents a premium of 42 percent to the closing price of Depomed on July 6, 2015. The transaction, if consummated, would be immediately and substantially accretive
The agreement will offer an additional source of the dolutegravir active pharmaceutical ingredient (API), and will allow ViiV Healthcare to offer a competitive supply of the finished product
The instrument will be based on Milestone Scientific’s painless, computer-controlled injection and drug delivery technology, which has commercial applications across a broad spectrum of medical and dental procedures.
This Notice of Allowance concludes the substantive examination of the patent application and will result in the issuance of a U.S. patent after administrative processes are completed. The
Narcan was the first naloxone product approved by the U.S. Food and Drug Administration (FDA) as a treatment for opioid overdose in 1971. Narcan has not been distributed
The trial is a follow-on study to a first Phase I/IIa study completed in 2014, enrolling 26 patients. Functioning as their own placebo, all patients were subjected to
Aspirin and extended-release dipyridamole capsules are used to lower the risk of stroke in people who have had a mini-stroke (transient ischemic attack or TIA) or stroke due
The collaboration brings together TES Pharma, a research-based biotech company led by Professor Roberto Pellicciari (Scientific Co-Founder of Intercept Pharmaceuticals, Inc) with state of the art research facilities
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.